Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide as Adjuvant Therapy for High-Risk Prostate Cancer Post-Prostatectomy
NCT07444983Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rezvilutamide in prostate cancer (PCa), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Biochemical Recurrence-Free Survival Rate at 36 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07444983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444983.